Cell MedX Corp. announced that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario has been completed. Nutrasource Diagnostics Inc., a contract research organization, has completed the final report on the Trial and has submitted it to Health Canada for final approval. The objective of the Trial was to assess eBalance therapy as an adjunct treatment for diabetes and related complications in Type 1 and Type 2 diabetics over three months. The secondary endpoints of the Trial observed changes from baseline in the following: Insulin sensitivity, Diabetic neuropathy, Diabetic foot pain and numbness, Wound healing, Blood pressure, Kidney function, and any other changes reported by patients. The company announced that all 30 subjects (100%) taking part in the Trial followed through to completion. This level of completion is considered to be unusually high, particularly since the subjects were required to come to the clinic twice a week for a period of three months after the initial screening and selection. The Trial resulted in several encouraging trends spanning a vast array of areas including HbA1c and secondary efficacy endpoints assessing insulin resistance, insulin sensitivity, blood pressure and kidney function following eBalance treatment. On average, the mean HbA1c decreased as compared to baseline. The post-treatment glucometer reading decreased relative to pre-treatment on most visits. A trend towards a decrease in markers assessing insulin resistance including fasting blood glucose, plasma insulin and HbA1c compared to baseline was noted. A marked decrease in blood pressure as measured by systolic and diastolic blood pressure was observed. A decrease in eGFR (estimated glomerular filtration rate used to assess kidney function) was also exhibited. Lastly, in regard to general pain, the Trial revealed that some subjects, without diagnosed complications, reported feeling less pain and/or coldness or numbness in their extremities. During the Trial there were no subjects with diabetic wounds so no results were observed in this area. The treatment was considered safe for the purposes of the Trial. There were no significant treatment-related adverse events or negative abnormalities in routine hematology, biochemistry, vital signs or physical findings for the duration of the Trial.